TY  - JOUR 
AU  - Mateos Manteca, María Victoria
AU  - Richardson, Paul G.
AU  - Schlag, Rudolf
AU  - Khuageva, Nuriet K
AU  - Dimopoulos, Meletios A.
AU  - Shpilberg, Ofer
AU  - Kropff, Martin
AU  - Spicka, Ivan
AU  - Petrucci, Maria T
AU  - Palumbo, Antonio
AU  - Samoilova, Olga S
AU  - Dmoszynska, Anna
AU  - Abdulkadyrov, Kudrat M
AU  - Schots, Rik
AU  - Jiang, Bin
AU  - Esseltine, Dixie-Lee
AU  - Liu, Kevin
AU  - Cakana, Andrew
AU  - van de Velde, Helgi
AU  - San Miguel Izquierdo, Jesús Fernando
PY  - 2010
UR  - http://hdl.handle.net/10366/154346
AB  - [EN]The purpose of this study was to confirm overall survival (OS) and other clinical benefits with bortezomib, melphalan, and prednisone (VMP) versus melphalan and prednisone (MP) in the phase III VISTA (Velcade as Initial Standard Therapy in...
LA  - eng
PB  - American Society of Clinical Oncology
KW  - Mieloma múltiple
KW  - Aged
KW  - Boronic Acids
KW  - Kaplan-Meier Estimate
KW  - Risk Assessment
KW  - Humans
KW  - Pyrazines
KW  - Melphalan
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Recurrence
KW  - Multiple Myeloma
KW  - Time Factors
KW  - Risk Factors
KW  - Treatment Outcome
KW  - Prednisone
TI  - Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial
DO  - 10.1200/JCO.2009.26.0638
T2  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
VL  - 28
M2  - 2259
ER  -